Effect of Low-Intensity Transcranial Focused Ultrasound Stimulation in Patients With Major Depressive Disorder: A Randomized, Double-Blind, Sham-Controlled Clinical Trial.
Authors: Oh J, Ryu JS, Kim J, Kim S, Jeong HS, Kim KR, Kim HC, Yoo SS, Seok JH
Low-intensity transcranial focused ultrasound (tFUS) has emerged as a promising non-invasive brain stimulation modality with high spatial selectivity and the ability to reach deep brain areas. The present study aimed to investigate the safety and effectiveness of low-intensity tFUS in treating major depressive disorder. Participants were recruited in an outpatient clinic and randomly assigned to either the verum tFUS or sham stimulation group. The intervention group received six sessions of tFUS stimulation to the left dorsolateral prefrontal cortex over two weeks. Neuropsychological assessments were conducted before and after the sessions. Resting-state functional magnetic resonance imaging (rsfMRI) was also performed to evaluate changes in functional connectivity (FC). The primary outcome measure was the change in depressive symptoms, assessed with the Montgomery-Åsberg Depression Rating Scale (MADRS). The tFUS stimulation sessions were well tolerated without any undesirable side effects. The analysis revealed a significant main effect of session sequence on the MADRS scores and significant interactions between the session sequences and groups. The rsfMRI analysis showed a higher FC correlation between the right superior part of the subgenual anterior cingulate cortex (sgACC) and several other brain regions in the verum group compared with the sham group. Our results reveal that tFUS stimulation clinically improved MADRS scores with network-level modulation of a sgACC subregion. This randomized, sham-controlled clinical trial, the first study of its kind, demonstrated the safety and probable efficacy of tFUS stimulation for the treatment of depression.
Introduction
Purpose
Transcranial ultrasound stimulation
Study Objective
To evaluate the safety and efficacy of low-intensity transcranial focused ultrasound (tFUS) for treating major depressive disorder.
Animal model / Human subject
Homo sapiens (human patients with major depressive disorder), strain: N/A, age: adults (19-60 years), sex: mixed (male and female)
Disease model
major depressive disorder
MRI or image guidance method
Image-guided navigation using co-registered MRI and CT with adhesive fiducial markers and real-time infrared camera tracking to align the FUS transducer to the left DLPFC target (MNI -42, 44, 30)
Targeted brain region(s)
Dorsolateral Prefrontal Cortex ( Dlpfc)
Target coordinates
MNI: -42, 44, 30
Outcomes and Safety
Summary of Outcomes
Low-intensity tFUS to the left dorsolateral prefrontal cortex (six sessions over two weeks; estimated in‑situ intensity ≈35.9% and mean targeting error 2.7±0.6 mm) was safe, produced greater reductions in depressive symptoms (MADRS) and suicidal ideation (SSI) versus sham, and increased functional connectivity between the right superior subgenual ACC and medial prefrontal, orbitofrontal, caudate and related regions.
Duration of biological effect
at least two weeks
Safety-related matter
tFUS sessions were well tolerated with no undesirable side effects or adverse events reported (no headache, scalp heating, hypersensitivity reaction, cerebral edema, microhemorrhage, or auditory phenomena). However, the trial lacked a formal blinding evaluation and did not assess for hypomanic switches, so some potential adverse effects were not formally evaluated.
Brain Region
Ultrasound Parameters
Ultrasound instrument
NS-US100 (Neurosona Co. Ltd, Seoul, Korea); transducer aperture/diameter: None
FUS Frequency
250 kHz
FUS Intensity
3 W/cm2 (spatial-peak pulse-average, I_sppa); 0.6 W/cm2 (in-situ spatial-peak temporal-average, estimated); 0.3 W/cm2 (spatial-peak temporal-average, reported)
FUS Pressure
0.3 MPa (peak negative pressure at focus, incident); ~0.135 MPa (estimated in‑situ)
FUS Mode
pulsed
Pulse duration
1 ms
Duration of a single FUS session
20 minutes
Focal Characteristics
Focal depth: 16.7±2.2 mm (verum), 18.4±2.9 mm (sham); Focal length: None; Aperture size: None
Treatment frequency
Multiple sessions
We are open to feedback. If you see a mistake or have a suggestion, please contact us.
← Back to Search